| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2026―Jul―03 |
Targeting HsDHODH: Shape and Machine-learning Guided Discovery and Structural Validation of SARS-CoV-2 Antivirals |
Luiza Vieira Cruz, Sabrina Silva-Mendonça, Aline Dias da Purificação, Melina Mottin, Miguel Arbeláez, Caroline S. Freitas, Natalia Fintelman-Rodrigues, Mayara Mattos, Thamires Quadros Froes, Christopher D. Jurisch, Donald Seanego, Grant A. Boyle, Fernanda de França Genuíno Ramos Campos, Thiago Moreno.L. Souza, Richard K. Gessner, Kelly Chibale, Maria Cristina Nonato, Carolina Horta Andrade |
| 2 |
[GO] |
2026―Jul―01 |
Structure-Guided Design of Potent and Selective Covalent Inhibitors of SARS-CoV-1 and SARS-CoV-2 Papain-like Proteases with Antiviral Activity |
Abdullah I. Al-Homoudi, Narva Deshwar Kushwaha, Hariprasad Aruri, Diego Galarza, Nathaniel J. Moorman, Mark T. Heise, Jacob Tartamella, Dipankar Ray, Ladislau C. Kovari, Navnath S. Gavande |
| 3 |
[GO] |
2026―Jun―25 |
Twin engines of viral replication: Medicinal chemistry insights on SARS-CoV-2 nsp12 and nsp13 |
Valentina Noemi Madia, Elisa Patacchini, Francesco Saccoliti, Laura Zarbo, Merve Arpacioglu, Roberta Costi, Roberto Di Santo |
| 4 |
[GO] |
2026―Jun―25 |
Exploring chemical space based on Transformation to design broad-spectrum 3CLpro inhibitors against coronavirus |
Zhihao Gu, Zhenkai Qi, Zhenfei Chen, Jiao Li, Shufen Song, Lu Liu, Jinlin Wang, Wenqi Zheng, Xiong Xie, Hong Liu, Xianglei Zhang, Wenhao Dai, Fang Bai |
| 5 |
[GO] |
2026―Jun―12 |
Discovery and evaluation of a 4-(benzothiazol-2-yl)-N-substituted aniline scaffold as MERS-CoV inhibitors |
Kaili Dai, Xiaomeng Zhang, Jun Dai, Minqi Hu, Jinjin Ren, Dandan Hu, Jie Tang, Chunlan Feng, Fan Wang, Yi Liu, Suxiang Li, Ting Liu, Ye Hong, Lifang Yu, Fan Yang, Wei Tang |
| 6 |
[GO] |
2026―May―22 |
Cephalosporins are potent SARS-CoV-2 main protease inhibitors |
Dorian-Gabriel Muntean, Wojtek Treyde, Dóra Laczi, Stephen M. Laidlaw, Eidarus Salah, Hani Choudhry, Miles W. Carroll, Fernanda Duarte, Christopher J. Schofield, Lennart Brewitz |
| 7 |
[GO] |
2026―Apr―30 |
Novobiocin Defines an Asn28 Allosteric Pocket that Governs SARS-CoV-2 Main Protease Activity |
Mohit Bhardwaj, Raushan Anjum, Sheetal Thakur, Pradeep Sharma, Ashok Kumar Patel |
| 8 |
[GO] |
2026―Apr―30 |
Discovery of Preclinical Candidate CG-0988, a Novel Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease Inhibitor Bearing Spirooxindole |
Xiubo Tang, Kai Hou, Xiaowu Chen, Wenyuan Fan, Hao Wu, Jia Meng, Changliang Lu, Gong-Xin He |
| 9 |
[GO] |
2026―Apr―07 |
Macrocycles and stapled-peptides in the fight against SARS-CoV-2: a review |
Santo Previti, Elsa Calcaterra, Florenci V. González, Carla Di Chio, Maria L. Calabrò, Roberta Ettari, Maria Zappalà |
| 10 |
[GO] |
2026―Feb―25 |
Discovery of a tetrahydrobenzothiophen-2-yl-pyrazolo[1,5-a]pyrimidine-3-carboxamide-based PROTAC as degrader of SARS-CoV-2 Main Protease |
Michela Eleuteri, Alessandro Bazzacco, Beatrice Mercorelli, Jenny Desantis, Alessia Zago, Gabriele Cruciani, Arianna Loregian, Laura Goracci |
| 11 |
[GO] |
2026―Jan―13 |
Design and Synthesis of Dual-Activity Biphenyl Inhibitors Against SARS-CoV-2 and Bladder Cancer |
Lin Lin Shang, Teng Long Hu, Situ Xiong, Songhui Xu, Li Ping Cheng |
| 12 |
[GO] |
2026―Jan―09 |
Trivalent triterpenoids block SARS-CoV-2 and influenza A virus infection by directly targeting homotrimeric envelope proteins |
Liwen Hua, Mengyang Wang, Qianqian Gao, Honggao Duan, Yiming Wang, Rui Feng, Yiping Zhong, Xingxing Zhu, Yu Mu, Yongmin Zhang, Demin Zhou, Sulong Xiao |
| 13 |
[GO] |
2026―Jan―08 |
Novel dual-functional peptides designed via NanoBiT spike pseudovirus system for real-time monitoring and inhibition of SARS-CoV-2 infection |
Cheng-Han Lin, Hua-Hsin Chiang, Xin-Rui Yang, Tzu-Ching Lin, Chin-Hung Tsai, Chih-Sheng Lin |
| 14 |
[GO] |
2025―Dec―18 |
Predictive modeling and fragment-based design of triterpenoid-nucleoside conjugates targeting coronavirus membrane fusion |
Mengyang Wang, Xingxing Zhu, Shouxin Wang, Honggao Duan, Liwen Hua, Yiping Zhong, Yiming Wang, Yu Mu, Tianxin Xiang, Mingyong Huang, Yongmin Zhang, Demin Zhou, Sulong Xiao |
| 15 |
[GO] |
2025―Dec―17 |
Discovery and SAR studies of antiviral 4-aminopiperidine derivatives active against SARS-CoV-2 |
Sergio Algar, Paula Bueno, Hristo Anatoliev-Dimitrov, Jessy Medina, Valentina Trifero, Victoria Castro, Urtzi Garaigorta, Pablo Gastaminza, Christophe Dardonville |
| 16 |
[GO] |
2025―Dec―16 |
Targeted Screening and Rational Optimization of Bazedoxifene Analogues as Pan-Variant SARS-CoV-2 Entry Inhibitors with Improved Pharmacokinetics |
Binita Patra, Nirmal Das, Akshay Joshi, Sahil Kumar, Renuga Devi, Biswajit Kundu, Nanda Kumar Raja, Israful Hoque, Soupayan Pal, Anindita Dey, Jafar Sarif, Nittu Singh, Nandha Kumaar, Ravneet Singh Chawla, Uddipta Ghosh Dastidar, Alna Kuriyickal Martin, Kanagasabai Balamurugan, Bokara Kiran Kumar, Rajesh P. Ringe, Dipyaman Ganguly, Krishan Gopal Thakur, Arindam Talukdar. |
| 17 |
[GO] |
2025―Dec―10 |
Corrigendum to “Thiol esters as chemical warheads of SARS-CoV-2 main protease (3CLpro) peptide-like inhibitors” [Eur. J. Med. Chem. 293 (2025) 117709] |
Xuehong Qiao, Menghan Cui, Zhiwei Yu, Ling Ma, Hailong Liu, Xingxing Yang, Yuan Chen, Dahong Li, Jinjing Che, Linxiang Zhao, Ruibin Su, Xuhong Ren, Shan Cen, Bin Lin, Xinhua He |
| 18 |
[GO] |
2025―Nov―29 |
Thiazolyl 4-Carboxylate Ketone as a New Warhead for a Highly Potent SARS-CoV-2 Main Protease Inhibitor |
Maria A. Theodoropoulou, Haifa El Kilani, Christiana Mantzourani, Dirk Jochmans, Johan Neyts, Kaixuan Zhang, Judith Röske, Maroula G. Kokotou, Rolf Hilgenfeld, George Kokotos |
| 19 |
[GO] |
2025―Nov―21 |
Inhibitors of membrane associated serine proteases block replication of coronavirus SARS-CoV-2 and influenza virus H1N1 |
Victoria Banas, Kuljeet Seehra, Matthew Mahoney, Carolina Alisio, Yevhenii Kyriukha, Elizabeth Weiland, Michelle Fath, Zhenfu Han, Traci Bricker, Michael Tartell, Sean Whelan, Adrianus C.M. Boon, James W. Janetka |
| 20 |
[GO] |
2025―Oct―28 |
A new chemotype that opens the S2∗ pocket of the 3CL protease exhibits antiviral activity against SARS-CoV-2 |
Laura Mourot, Fatima-Zahra Chaibi, Nour Bou-Karroum, Paul Carré, Alberto Abengozar Munoz, Valérie Landry, Audrey Tarricone, Alexandre Biela, Catherine Piveteau, Gleb Novikov, Elian Dupré, Jean Dubuisson, Sandrine Belouzard, Florence Leroux, Benoit Deprez, Xavier Hanoulle, Julie Charton |
| 21 |
[GO] |
2025―Sep―06 |
Mitigating SARS-CoV-2-Exacerbated Neuroinflammation and Alzheimer’s Pathology: Synthesis of Quinoline-Based Dual Inhibitors Targeting Cysteine and Aspartyl Proteases |
Abid Hussain Khan, Anees Saeed, Amal Balqees Gondal, Fahad Hussain, Ayesha Tahir, Iltaf Shah, Umer Rashid, Abbas Hassan |
| 22 |
[GO] |
2025―Jul―07 |
Structure-activity relationship studies of thiazole-based derivatives leading to the identification of novel and potent SARS-CoV-2 main protease inhibitors |
Weile Yin, Wai-Po Kong, Siu-Lun Leung, Cheung-Hin Hung, Kwok-Yin Wong |
| 23 |
[GO] |
2025―Jun―21 |
Targeting Dihydroorotate Dehydrogenase (DHODH) for Host-Directed Therapy: Discovery of a Novel Alkyne-Based Scaffold Inhibitor Effective Against SARS-CoV-2 |
Miguel M. Vaidergorn, Aline D. Purificação, Pedro I.P. Leite, Sabrina Silva-Mendonça, Wemenes J.L. Silva, Thiago dos Santos, Daniel Gedder Silva, Bruna Fleck Godoi, Carolina Q. Sacramento, Mayara Mattos, Natalia Fintelman-Rodrigues, Caroline S. Freitas, Luis Eduardo Alves Damasceno, Yoko Shishikura, Alex Brown, Karolina Wrobel, Jennifer Riley, Thiago M.L. Souza, Kevin D. Read, José C. Alves-Filho, Carolina H. Andrade, M. Cristina Nonato, Flavio S. Emery |
| 24 |
[GO] |
2025―May―06 |
Thiol esters as chemical warheads of SARS-CoV-2 main protease (3CLpro) peptide-like inhibitors |
Xuehong Qiao, Menghan Cui, Zhiwei Yu, Ling Ma, Hailong Liu, Xingxing Yang, Yuan Chen, Dahong Li, Jinjing Che, Linxiang Zhao, Ruibin Su, Xuhong Ren, Shan Cen, Bin Lin, Xinhua He |
| 25 |
[GO] |
2025―Apr―08 |
Silaproline-bearing nirmatrelvir derivatives are potent inhibitors of the SARS-CoV-2 main protease highlighting the value of silicon-derivatives in structure-activity-relationship studies |
Dóra Laczi, Sofia Schönbauer Huamán, Taylah Andrews-Clark, Stephen M. Laidlaw, Eidarus Salah, Leo Dumjahn, Petra Lukacik, Hani Choudhry, Martin A. Walsh, Miles W. Carroll, Christopher J. Schofield, Lennart Brewitz |
| 26 |
[GO] |
2025―Apr―07 |
A deep learning model for structure-based bioactivity optimization and its application in the bioactivity optimization of a SARS-CoV-2 main protease inhibitor |
Zhenyu Yang, Kai Wang, Guo Zhang, Yuanyuan Jiang, Rui Zeng, Jingxin Qiao, Yueyue Li, Xinyue Deng, Ziyi Xia, Rui Yao, Xiaoxi Zeng, Liyun Zhang, Yi Zhao, Jian Lei, Runsheng Chen |
| 27 |
[GO] |
2025―Mar―13 |
Development of Acylhydrazone Linked Thiazoles as Non-Covalent Dual Inhibitors of SARS-CoV-2 Proteases |
Vidya Jyothi Alli, Shubham Kumar Singh, Mounika Darna, Vavilapalli Suresh, Swapnil Anil Sule, Aruna Jangam, Bhavita Kattula, Sarva Lakshmi Pusarapu, Jessie Thomas, Yogesh Sardana, Krishna Prasad Gundla, Amarender Goud Burra, Kunta Chandra Sekhar, Samata Sai Patnaik, Bharati Reddi, Kathirvel Muralidharan, Kiran Kumar Bokara, Anthony Addlagatta, Surender Singh Jadav |
| 28 |
[GO] |
2025―Mar―10 |
Expanding the utilization of binding pockets proves to be effective for noncovalent small molecule inhibitors against SARS-CoV-2 Mpro |
Qi Yang, Xupeng Huang, Hongbo Zhang, Jing Sun, Jielin Tang, Zhao Chen, Lijie Liu, Man Liu, Zeyun Sun, Zhenhao Tang, Dandan Wei, Dong Wang, Yiliang Wang, Mengrong Yan, Li Zhao, Airu Zhu, Yihang Zhong, Haitao Yang, Yao Zhao, Jun Dai, Yongxia Shi, Bo Huang, Wei Zhang, Jincun Zhao, Xinwen Chen, Zihe Rao, Wei Peng |
| 29 |
[GO] |
2025―Feb―25 |
High-affinity, broad-spectrum, "centipede-like" multi-branched drug conjugates, anchored to the S protein, for blocking coronavirus infection |
Huatai Zhu, Xuan Liu, Jing He, Jiandu Lei, Jingyang Zhao |
| 30 |
[GO] |
2025―Feb―20 |
Discovery and optimization of Phenazopyridine hydrochloride as novel SARS-CoV-2 RdRp inhibitors |
Jianyuan Zhao, Guoning Zhang, YaSheng Li, Ling Ma, Dongrong Yi, Quanjie Li, Yu Shi, Saisai Guo, Tianfu Liu, Yujia Wang, Xiaoyu Li, Yucheng Wang, Wenjie Tan, Jiabin Li, Shan Cen |
| 31 |
[GO] |
2025―Jan―21 |
The Chiral 5,6-Cyclohexane-fused Uracil Ring-System: a Molecular Platform with Promising Activity against SARS-CoV-2 |
Enrico Marcantonio, Debora Guazzetti, Crescenzo Coppa, Lucia Battistini, Andrea Sartori, Kelly Bugatti, Becky Provinciael, Claudio Curti, Alessandro Contini, Kurt Vermeire, Franca Zanardi |
| 32 |
[GO] |
2025―Jan―20 |
Design, Synthesis, and Antiviral Activity of Fragmented-Lapatinib Aminoquinazoline Analogs towards SARS-CoV-2 Inhibition |
Ayomide Adediji, Akeanan Sroithongmoon, Aphinya Suroengrit, Patcharin Wilasluck, Peerapon Deetanya, Kamonpan Sanachai, Kun Karnchanapandh, Siwaporn Boonyasuppayakorn, Kittikhun Wangkanont, Thanyada Rungrotmongkol, Tanatorn Khotavivattana |
| 33 |
[GO] |
2024―Oct―30 |
Discovery of peptidomimetic spiropyrrolidine derivatives as novel 3CLpro inhibitors against SARS-CoV-2 |
Samuel Desta Guma, Zhaoyin Zhou, Kang Song, Feipu Yang, Jin Suo, Yan Zhang, Emmanuel Mintah Bonku, Abdullajon Odilov, Guanghui Tian, Zhijian Xu, Xiangrui Jiang, Qiumeng Zhang, Weiliang Zhu, Jingshan Shen |
| 34 |
[GO] |
2024―Oct―18 |
Naphthalen-1-ylethanamine-containing small molecule inhibitors of the papain-like protease of SARS-CoV-2 |
Kouki Shinohara, Takuya Kobayakawa, Kohei Tsuji, Yuki Takamatsu, Hiroaki Mitsuya, Hirokazu Tamamura |
| 35 |
[GO] |
2024―Sep―19 |
Utilizing artificial intelligence for precision exploration of N protein targeting phenanthridine sars-cov-2 inhibitors: A novel approach |
Zheng-rui Xiang, Shi-rui Fan, Juan Ren, Ting Ruan, Yuan Chen, Yun-wu Zhang, Yi-ting Wang, Ze-zhou Yu, Chao-fan Wang, Xiao-long Sun, Xiao-Jiang Hao, Duo-Zhi Chen |
| 36 |
[GO] |
2024―Sep―16 |
Exploration of isatin-based inhibitors of SARS-CoV-2 Nsp15 endoribonuclease |
Theodoros Rampias, Thomas Antoniou, Annelies Stevaert, Lara Kravariti, Benjamin Van Loy, Julie Vandeput, Jacopo Sgrignani, Natalia Filippidou, Patrizia Locatelli, Martina Samiotaki, Eleftherios Paraskevas Tzakos, Andrea Cavalli, Lieve Naesens, Diamantis C. Sideris, Andreas G. Tzakos |
| 37 |
[GO] |
2024―Sep―04 |
How many organic small molecules might be used to treat COVID-19? From natural products to synthetic agents |
Zai-Qun Liu |
| 38 |
[GO] |
2024―Aug―08 |
Covalent small-molecule inhibitors of SARS-CoV-2 Mpro: Insights into their design, classification, biological activity, and binding interactions |
Ahmed M. Shawky, Faisal A. Almalki, Hayat Ali Alzahrani, Ashraf N. Abdalla, Bahaa G.M. Youssif, Nashwa A. Ibrahim, Mohammed Gamal, Hany A.M. El-Sherief, Maha M. Abdel-Fattah, Ahmed A. Hefny, Ahmed H. Abdelazeem, Ahmed M. Gouda |
| 39 |
[GO] |
2024―Jul―24 |
N-Acylbenzimidazoles as Selective Acylators of the Catalytic Cystein of the Coronavirus 3CL Protease. |
Fatima-Zahra Chaibi, Lucile Brier, Paul Carré, Valérie Landry, Lowiese Desmarets, Audrey Tarricone, François-Xavier Cantrelle, Danai Moschidi, Adrien Herledan, Alexandre Biela, Fanny Bourgeois, Chloé Ribes, Sarah Ikherbane, Mathilde Malessan, Jean Dubuisson, Sandrine Belouzard, Xavier Hanoulle, Florence Leroux, Benoit Deprez, Julie Charton |
| 40 |
[GO] |
2024―Jul―11 |
Novel compounds with dual inhibition activity against SARS-CoV-2 critical enzymes RdRp and human TMPRSS2 |
Sameh.S.M. Soliman, Alshaimaa M. Hamoda, Yogendra Nayak, Ahmed Mostafa, Rania Hamdy |
| 41 |
[GO] |
2024―Jun―25 |
Development of novel antivrial agents that induce the degradation of the main protease of human-infecting coronaviruses |
Shuihong Cheng, Yong Feng, Wei Li, Tong Liu, Xun Lv, Xiaomei Tong, Gan Xi, Xin Ye, Xuebing Li |
| 42 |
[GO] |
2024―May―16 |
Discovery of meisoindigo derivatives as noncovalent and orally available Mpro inhibitors: their therapeutic implications in the treatment of COVID-19 |
Qingtian Gao, Sixu Liu, Yuzheng Zhou, Jinbao Fan, Shufen Ke, Yuqing Zhou, Kaiqiang Fan, Yuxuan Wang, Yingjun Zhou, Zanxian Xia, Xu Deng |
| 43 |
[GO] |
2024―Apr―25 |
Medicinal chemistry strategies toward broad-spectrum antiviral agents to prevent next pandemics |
Zirui Lü, Xiandong Dai, Jianjie Xu, Zhenming Liu, Yongbiao Guo, Zhenhua Gao, Fanhua Meng |
| 44 |
[GO] |
2024―Feb―24 |
Synthesis and biological evaluation of novel Peptidomimetic inhibitors of the coronavirus 3C-like protease |
Franck Amblard, Julia C. Le Cher, Ramyani De, Shaoman Zhou, Peng Liu, Shu Ling Goh, Sijia Tao, Dharmeshkumar Patel, Jessica Downs-Bowen, Keivan Zandi, Huanchun Zhang, Gitika Chaudhry, Tamara McBrayer, Michael Muczynski, Abdullah Al-Homoudi, Joseph Engel, Shuiyun Lan, Stefan G. Sarafianos, Ladislau C. Kovari, Raymond F. Schinazi |
| 45 |
[GO] |
2024―Feb―12 |
Design, synthesis and biological evaluation of novel 1,2,4a,5-tetrahydro-4H-benzo[b][1,4]oxazino[4,3-d][1,4]oxazine-based AAK1 inhibitors with anti-viral property against SARS-CoV-2 |
Nian-Dong Mao, Yueying Xu, Hao Che, Xia Yao, Yuan Gao, Chenchen Wang, Haowen Deng, Zi Hui, Hang Zhang, Xiang-Yang Ye |
| 46 |
[GO] |
2024―Feb―06 |
Design, synthesis, and biological evaluation of first-in-class indomethacin-based PROTACs degrading SARS-CoV-2 main protease and with broad-spectrum antiviral activity |
Jenny Desantis, Alessandro Bazzacco, Michela Eleuteri, Sara Tuci, Elisa Bianconi, Antonio Macchiarulo, Beatrice Mercorelli, Arianna Loregian, Laura Goracci |
| 47 |
[GO] |
2024―Feb―01 |
Exploration of P1 and P4 modifications of nirmatrelvir: Design, synthesis, biological evaluation, and X-ray structural studies of SARS-CoV-2 Mpro inhibitors |
Arun K. Ghosh, Monika Yadav, Satyanarayana Iddum, Somayeh Ghazi, Emma K. Lendy, Uttara Jayashankar, Sydney N. Beechboard, Yuki Takamatsu, Shin-ichiro Hattori, Masayuki Aamano, Nobuyo Higashi-Kuwata, Hiroaki Mitsuya, Andrew D. Mesecar |
| 48 |
[GO] |
2024―Jan―09 |
Peptidomimetics as potent dual SARS-CoV-2 cathepsin-L and main protease inhibitors: In silico design, synthesis and pharmacological characterization |
Tania Ciaglia, Vincenzo Vestuto, Veronica Di Sarno, Simona Musella, Gerardina Smaldone, Francesca Di Matteo, Valeria Napolitano, Maria Rosaria Miranda, Giacomo Pepe, Manuela Giovanna Basilicata, Sara Novi, Ilaria Capolupo, Giuseppe Bifulco, Pietro Campiglia, Isabel Gomez-Monterrey, Robert Snoeck, Graciela Andrei, Michele Manfra, Carmine Ostacolo, Gianluigi Lauro, Alessia Bertamino |
| 49 |
[GO] |
2023―Dec―05 |
Structure-based design of SARS-CoV-2 papain-like protease inhibitors |
Prakash Jadhav, Bo Huang, Jerzy Osipiuk, Xiaoming Zhang, Haozhou Tan, Christine Tesar, Michael Endres, Robert Jedrzejczak, Bin Tan, Xufang Deng, Andrzej Joachimiak, Jianfeng Cai, Jun Wang |
| 50 |
[GO] |
2023―Nov―30 |
Plant-derived strategies to fight against severe acute respiratory syndrome coronavirus 2 |
Wenkang Li, Tianze Ding, Huimin Chang, Yuanchang Peng, Jun Li, Xin Liang, Huixin Ma, Fuguang Li, Maozhi Ren, Wang Wenjing |
| 51 |
[GO] |
2023―Nov―25 |
Development of de-novo coronavirus 3-chymotrypsin-like protease (3CLpro) inhibitors since COVID-19 outbreak: A strategy to tackle challenges of persistent virus infection |
Lei Tian, Taotao Qiang, Xiuding Yang, Yue Gao, Xiaopei Zhai, Kairui Kang, Cong Du, Qi Lu, Hong Gao, Dezhu Zhang, Xiaolin Xie, Chengyuan Liang |
| 52 |
[GO] |
2023―Nov―25 |
Design, synthesis and biological evaluation of biaryl amide derivatives against SARS-CoV-2 with dual-target mechanism |
Jiayu Li, Xiuli Zhong, Hongying Li, Zhihui Yu, Jianrui Li, Qionglu Duan, Yinghong Li, Fenbei Chen, Yanxiang Wang, Zhiyun Wu, Yonghua Liu, Zonggen Peng, Danqing Song |
| 53 |
[GO] |
2023―Nov―01 |
Highly potent dual-targeting angiotensin-converting enzyme 2 (ACE2) and Neuropilin-1 (NRP1) peptides: A promising broad-spectrum therapeutic strategy against SARS-CoV-2 infection |
Shuang Mei, Yunting Zou, Su Jiang, Lu Xue, Yuting Wang, Han Jing, Peng Yang, Miao-Miao Niu, Jindong Li, Kai Yuan, Yan Zhang |
| 54 |
[GO] |
2023―Oct―31 |
Targeting SARS-CoV-2 entry processes: The promising potential and future of host-targeted small-molecule inhibitors |
Aijia Wu, Kunyu Shi, Jiaxing Wang, Ruofei Zhang, Yuxi Wang |
| 55 |
[GO] |
2023―Sep―25 |
Design, synthesis, and structure-activity relationships of a novel class of quinazoline derivatives as coronavirus inhibitors |
Shengchao Zhou, Kun Wang, Ziwei Hu, Tao Chen, Yao Dong, Rongmei Gao, Mengyuan Wu, Yuhuan Li, Xingyue Ji |
| 56 |
[GO] |
2023―Aug―28 |
Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review |
Xin Li, Yongcheng Song |
| 57 |
[GO] |
2023―Aug―28 |
Synthesis of cannabidiol-based compounds as ACE2 inhibitors with potential application in the treatment of COVID-19 |
Gabriel Vitor de Lima Marques, Daisymara Priscila de Almeida Marques, Felipe Alves Clarindo, Jesus Alberto Avendaño-Villarreal, Fabiana Sélos Guerra, Patrícia Dias Fernandes, Eduardo Nicolau dos Santos, Elena Vitalievna Gusevskaya, Markus Kohlhoff, Fabrício de Araújo Moreira, Luis Adan Flores Andrade, Flávio Guimarães da Fonseca, Jordana Grazziela Alves Coelho dos-Reis, Renata Barbosa de Oliveira |
| 58 |
[GO] |
2023―Aug―18 |
Discovery of antiviral SARS-CoV-2 main protease inhibitors by structure-guided hit-to-lead optimization of carmofur |
Koon Mook Kang, Yejin Jang, Sang Soo Lee, Mi Sun Jin, Chang-Duk Jun, Meehyein Kim, Yong-Chul Kim |
| 59 |
[GO] |
2023―Aug―17 |
Discovery of highly potent covalent SARS-CoV-2 3CLpro inhibitors bearing 2-sulfoxyl-1,3,4-oxadiazole scaffold for combating COVID-19 |
Fu-Mao Zhang, Ting Huang, Feng Wang, Gui-Shan Zhang, Donglan Liu, Jun Dai, Jian-Wei Zhang, Qing-Hua Li, Guo-Qiang Lin, Dingding Gao, Jincun Zhao, Ping Tian |
| 60 |
[GO] |
2023―Aug―13 |
Novel mono- and multivalent N-acetylneuraminic acid glycoclusters as potential broad-spectrum entry inhibitors for influenza and coronavirus infection |
Xingxing Zhu, Yanliang Yi, Zibo Fan, Ruiwen Liu, Xindang Chu, Mengyang Wang, Jiayi Zhang, Elena Tretyakova, Yongmin Zhang, Lihe Zhang, Demin Zhou, Sulong Xiao |
| 61 |
[GO] |
2023―Aug―10 |
A comprehensive review on the global efforts on vaccines and repurposed drugs for combating COVID-19 |
Narva Deshwar Kushwaha, Jivanka Mohan, Babita Kushwaha, Terisha Ghazi, Joshua C. Nwabuife, Neil Koorbanally, Anil A. Chuturgoon |
| 62 |
[GO] |
2023―Jul―20 |
Discovery and structure-activity relationship studies of novel α-ketoamide derivatives targeting the SARS-CoV-2 main protease |
Chong Huang, Rui Zeng, Jingxin Qiao, Baoxue Quan, Ronghua Luo, Qiao Huang, Nihong Guo, Yueyue Li, Xinyan Long, Ronggang Ma, Anjie Xia, Zhen Fang, Yifei Wang, Yueshan Li, Yongtang Zheng, Linli Li, Jian Lei, Shengyong Yang |
| 63 |
[GO] |
2023―Jul―19 |
Exploring diverse reactive warheads for the design of SARS-CoV-2 main protease inhibitors |
Bin Tan, Michael Sacco, Haozhou Tan, Kan Li, Ryan Joyce, Xiujun Zhang, Yu Chen, Jun Wang |
| 64 |
[GO] |
2023―May―24 |
Discovery of quinazolin-4-one-based non-covalent inhibitors targeting the severe acute respiratory syndrome coronavirus 2 main protease (SARS-CoV-2 Mpro) |
Kuojun Zhang, Tianyu Wang, Maotian Li, Mu Liu, He Tang, Lin Wang, Ke Ye, Jiamei Yang, Sheng Jiang, Yibei Xiao, Youhua Xie, Meiling Lu, Xiangyu Zhang |
| 65 |
[GO] |
2023―May―23 |
Design, synthesis and biological evaluation of peptidomimetic benzothiazolyl ketones as 3CLpro inhibitors against SARS-CoV-2 |
Hanxi Yang, Mengyuan You, Xiaoyang Shu, Jingyao Zhen, Mengwei Zhu, Tiantian Fu, Yan Zhang, Xiangrui Jiang, Leike Zhang, Yechun Xu, Yumin Zhang, Haixia Su, Qiumeng Zhang, Jingshan Shen |
| 66 |
[GO] |
2023―May―22 |
The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022 |
Xiaojing Pang, Wei Xu, Yang Liu, Hua Li, Lixia Chen |
| 67 |
[GO] |
2023―May―11 |
Structure-guided optimization of adenosine mimetics as selective and potent inhibitors of coronavirus nsp14 N7-methyltransferases |
Marcel Hausdorff, Adrien Delpal, Sarah Barelier, Laura Nicollet, Bruno Canard, Franck Touret, Agathe Colmant, Bruno Coutard, Jean-Jacques Vasseur, Etienne Decroly, Françoise Debart |
| 68 |
[GO] |
2023―Apr―17 |
Discovery of novel papain-like protease inhibitors for potential treatment of COVID-19 |
Fatema Hersi, Anusha Sebastian, Hamadeh Tarazi, Vunnam Srinivasulu, Ahmed Mostafa, Abdou Kamal Allayeh, Cong Zeng, Ibrahim Y. Hachim, Shan-Lu Liu, Imad A. Abu-Yousef, Amin F. Majdalawieh, Dana M. Zaher, Hany A. Omar, Taleb H. Al-Tel |
| 69 |
[GO] |
2023―Apr―15 |
Structure-guided design of direct-acting antivirals that exploit the gem-dimethyl effect and potently inhibit 3CL proteases of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) and middle east respiratory syndrome coronavirus (MERS-CoV) |
Chamandi S. Dampalla, Matthew J. Miller, Yunjeong Kim, Alexandria Zabiegala, Harry Nhat Nguyen, Trent K. Madden, Hayden A. Thurman, Alexandra J. Machen, Anne Cooper, Lijun Liu, Kevin P. Battaile, Scott Lovell, Kyeong-Ok Chang, William C. Groutas |
| 70 |
[GO] |
2023―Mar―31 |
Broad-spectrum coronavirus 3C-like protease peptidomimetic inhibitors effectively block SARS-CoV-2 replication in cells: Design, synthesis, biological evaluation, and X-ray structure determination |
Irina Stefanelli, Angela Corona, Carmen Cerchia, Emilia Cassese, Salvatore Improta, Elisa Costanzi, Sveva Pelliccia, Stefano Morasso, Francesca Esposito, Annalaura Paulis, Sante Scognamiglio, Francesco Saverio Di Leva, Paola Storici, Margherita Brindisi, Enzo Tramontano, Rolando Cannalire, Vincenzo Summa |
| 71 |
[GO] |
2023―Mar―18 |
Potential RNA-dependent RNA polymerase inhibitors as prospective drug candidates for SARS-CoV-2 |
Mohamed S. Bekheit, Siva S. Panda, Adel S. Girgis |
| 72 |
[GO] |
2023―Mar―13 |
Repurposing 1,2,4-oxadiazoles as SARS-CoV-2 PLpro inhibitors and investigation of their possible viral entry blockade potential |
Mohammed Salah Ayoup, Mariam M. ElShafey, Hamida Adbel-hamid, Doaa A. Ghareeb, Marwa M. Abu-Serie, Lamia A. Heikal, Mohamed Teleb |
| 73 |
[GO] |
2023―Feb―28 |
Korupensamine A, but not its atropisomer, korupensamine B, inhibits SARS-CoV-2 in vitro by targeting its main protease (Mpro) |
Ahmed M. Sayed, Alyaa Hatem Ibrahim, Nasir Taj�n, Jürgen Seibel, Jochen Bodem, Nina Geiger, Kathrin Striffler, Gerhard Bringmann, Usama Ramadan Abdelmohsen |
| 74 |
[GO] |
2023―Feb―06 |
Novel dithiocarbamates selectively inhibit 3CL protease of SARS-CoV-2 and other coronaviruses |
Lucile Brier, Haitham Hassan, Xavier Hanoulle, Valerie Landry, Danai Moschidi, Lowiese Desmarets, Yves Rouillé, Julie Dumont, Adrien Herledan, Sandrine Warenghem, Catherine Piveteau, Paul Carré, Sarah Ikherbane, François-Xavier Cantrelle, Elian Dupré, Jean Dubuisson, Sandrine Belouzard, Florence Leroux, Benoit Deprez, Julie Charton |
| 75 |
[GO] |
2023―Jan―28 |
Development of indolealkylamine derivatives as potential multi-target agents for COVID-19 treatment |
Jyoti Chauhan, Erika Cecon, Nedjma Labani, Florence Gbahou, Fernando Real, Morgane Bomsel, Kshatresh Dutta Dubey, Ranajit Das, Julie Dam, Ralf Jockers, Subhabrata Sen |
| 76 |
[GO] |
2023―Jan―18 |
Discovery, synthesis and mechanism study of 2,3,5-substituted [1,2,4]-thiadiazoles as covalent inhibitors targeting 3C-Like protease of SARS-CoV-2 |
Pengxuan Ren, Changyue Yu, Ruxue Zhang, Tianqing Nie, Qiaoyu Hu, Hui Li, Xianglei Zhang, Xueyuan Zhang, Shiwei Li, Lu Liu, Wenhao Dai, Jian Li, Yechun Xu, Haixia Su, Leike Zhang, Hong Liu, Fang Bai |
| 77 |
[GO] |
2023―Jan―17 |
Identification of a short ACE2-derived stapled peptide targeting the SARS-CoV-2 spike protein |
Lorenzo Calugi, Giulia Sautariello, Elena Lenci, Mauro Leucio Mattei, Crescenzo Coppa, Nicoletta Cini, Alessandro Contini, Andrea Trabocchi |
| 78 |
[GO] |
2023―Jan―10 |
Nonsteroidal anti-inflammatory drugs (NSAIDs) and nucleotide analog GS-441524 conjugates with potent in vivo efficacy against coronaviruses |
Qifan Zhou, Yinzhu Luo, Yujun Zhu, Qishu Chen, Jingfei Qiu, Feng Cong, Yingjun Li, Xumu Zhang |
| 79 |
[GO] |
2022―Dec―15 |
Structure-based lead optimization of peptide-based vinyl methyl ketones as SARS-CoV-2 main protease inhibitors |
Santo Previti, Roberta Ettari, Elsa Calcaterra, Salvatore Di Maro, Stefan J. Hammerschmidt, Christin Müller, John Ziebuhr, Tanja Schirmeister, Sandro Cosconati, Maria Zappalà |
| 80 |
[GO] |
2022―Oct―19 |
Rational design of the zonulin inhibitor AT1001 derivatives as potential anti SARS-CoV-2 |
Simone Di Micco, Rahila Rahimova, Marina Sala, Maria C. Scala, Giovanni Vivenzio, Simona Musella, Graciela Andrei, Kim Remans, Léa Mammri, Robert Snoeck, Giuseppe Bifulco, Francesca Di Matteo, Vincenzo Vestuto, Pietro Campiglia, José A. Márquez, Alessio Fasano |
| 81 |
[GO] |
2022―Oct―17 |
Easy access to α-ketoamides as SARS-CoV-2 and MERS Mpro inhibitors via the PADAM oxidation route |
Sveva Pelliccia, Carmen Cerchia, Francesca Esposito, Rolando Cannalire, Angela Corona, Elisa Costanzi, Maria Kuzikov, Philip Gribbon, Andrea Zaliani, Margherita Brindisi, Paola Storici, Enzo Tramontano, Vincenzo Summa |
| 82 |
[GO] |
2022―Oct―03 |
Discovery of novel SARS-CoV-2 3CL protease covalent inhibitors using deep learning-based screen |
Liying Wang, Zhongtian Yu, Shiwei Wang, Zheng Guo, Qi Sun, Luhua Lai |
| 83 |
[GO] |
2022―Jul―11 |
Discovery of potent Benzoxaborole inhibitors against SARS-CoV-2 main and dengue virus proteases |
Nikos Kühl, Johannes Lang, Mila M. Leuthold, Christian D. Klein |
| 84 |
[GO] |
2022―Jul―08 |
A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals |
Yugendar R. Alugubelli, Zhi Zachary Geng, Kai S. Yang, Namir Shaabani, Kaustav Khatua, R. Ma Xinyu, Erol C. Vatansever, Chia-Chuan Cho, Yuying Ma, Jing Xiao, Lauren R. Blankenship, Ge Yu, Banumathi Sankaran, Pingwei Li, Robert Allen, Henry Ji, Shiqing Xu, Wenshe Ray Liu |
| 85 |
[GO] |
2022―Jul―03 |
Chalcone-amide, a privileged backbone for the design and development of selective SARS-CoV/SARS-CoV-2 papain-like protease inhibitors |
Mehdi Valipour |
| 86 |
[GO] |
2022―Jun―27 |
A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antivirals |
Yuying Ma, Kai S. Yang, Zhi Zachary Geng, Yugendar R. Alugubelli, Namir Shaabani, Erol C. Vatansever, Xinyu R. Ma, Chia-Chuan Cho, Kaustav Khatua, Jing Xiao, Lauren R. Blankenship, Ge Yu, Banumathi Sankaran, Pingwei Li, Robert Allen, Henry Ji, Shiqing Xu, Wenshe Ray Liu |
| 87 |
[GO] |
2022―Jun―03 |
Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease |
Xiaodong Dou, Qi Sun, Guofeng Xu, Yameng Liu, Caifang Zhang, Bingding Wang, Yangbin Lu, Zheng Guo, Lingyu Su, Tongyu Huo, Xinyi Zhao, Chen Wang, Zhongtian Yu, Song Song, Liangren Zhang, Zhenming Liu, Luhua Lai, Ning Jiao |
| 88 |
[GO] |
2022―May―13 |
The structure-based design of peptidomimetic inhibitors against SARS-CoV-2 3C like protease as Potent anti-viral drug candidate |
Hao Wang, Rongjuan Pei, Xin Li, Weilong Deng, Shuai Xing, Yanan Zhang, Chen Zhang, Shuai He, Hao Sun, Shuqi Xiao, Jin Xiong, Yecheng Zhang, Xinwen Chen, Yaxin Wang, Yu Guo, Bo Zhang, Luqing Shang |
| 89 |
[GO] |
2022―May―07 |
Identification, optimization, and biological evaluation of 3-O-β-chacotriosyl ursolic acid derivatives as novel SARS-CoV-2 entry inhibitors by targeting the prefusion state of spike protein |
Hui Li, Chen Cheng, Shanshan Shi, Yan Wu, Yongfeng Gao, Zhihao Liu, Mingjian Liu, Zhaodong Li, Lijian Huo, Xiapyan Pan, Shuwen Liu, Gaopeng Song |
| 90 |
[GO] |
2022―Mar―19 |
Design, synthesis and biological evaluation of niclosamide analogs against SARS-CoV-2 |
Yu-Pu Juang, Yu-Ting Chou, Ru-Xian Lin, Hsiu-Hua Ma, Tai-Ling Chao, Jia-Tsrong Jan, Sui-Yuan Chang, Pi-Hui Liang |
| 91 |
[GO] |
2022―Feb―04 |
Antioxidant, anti-inflammatory and immunomodulatory roles of vitamins in COVID-19 therapy |
Aurelia Magdalena Pisoschi, Aneta Pop, Florin Iordache, Loredana Stanca, Ovidiu Ionut Geicu, Liviu Bilteanu, Andreea Iren Serban |
| 92 |
[GO] |
2022―Jan―23 |
In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease |
Muya Xiong, Tianqing Nie, Qiang Shao, Minjun Li, Haixia Su, Yechun Xu |
| 93 |
[GO] |
2022―Jan―13 |
Development of targeted nanoparticles loaded with antiviral drugs for SARS-CoV-2 inhibition |
Vanna Sanna, Sandro Satta, Tzung Hsiai, Mario Sechi |
| 94 |
[GO] |
2021―Dec―11 |
Design, synthesis and in vitro evaluation of novel SARS-CoV-2 3CLpro covalent inhibitors |
Julia K. Stille, Jevgenijs Tjutrins, Guanyu Wang, Felipe A. Venegas, Christopher Hennecker, Andrés M. Rueda, Itai Sharon, Nicole Blaine, Caitlin E. Miron, Sharon Pinus, Anne Labarre, Jessica Plescia, Mihai Burai Patrascu, Xiaocong Zhang, Alexander S. Wahba, Danielle Vlaho, Mitchell J. Huot, T. Martin Schmeing, Anthony K. Mittermaier, Nicolas Moitessier |
| 95 |
[GO] |
2021―Dec―01 |
Discovery of 9,10-dihydrophenanthrene derivatives as SARS-CoV-2 3CLpro inhibitors for treating COVID-19 |
Jian-Wei Zhang, Yuan Xiong, Feng Wang, Fu-Mao Zhang, Xiaodi Yang, Guo-Qiang Lin, Ping Tian, Guangbo Ge, Dingding Gao |
| 96 |
[GO] |
2021―Nov―01 |
Novel nucleocapsid protein-targeting phenanthridine inhibitors of SARS-CoV-2 |
Yi-Ting Wang, Xin-Yan Long, Xiao Ding, Shi-Rui Fan, Jie-Yun Cai, Bi-Juan Yang, Xin-Fang Zhang, Rong-hua Luo, Lian Yang, Ting Ruan, Juan Ren, Chen-Xu Jing, Yong-Tang Zheng, Xiao-Jiang Hao, Duo-Zhi Chen |
| 97 |
[GO] |
2021―Oct―05 |
Screening S protein - ACE2 blockers from natural products: Strategies and advances in the discovery of potential inhibitors of COVID-19 |
Le-le Ma, Hui-min Liu, Xue-mei Liu, Xiao-yu Yuan, Chao Xu, Fang Wang, Jun-zhi Lin, Run-chun Xu, Ding-kun Zhang |
| 98 |
[GO] |
2021―Sep―22 |
Identification of a dual acting SARS-CoV-2 proteases inhibitor through in silico design and step-by-step biological characterization |
Veronica Di Sarno, Gianluigi Lauro, Simona Musella, Tania Ciaglia, Vincenzo Vestuto, Marina Sala, Maria Carmina Scala, Gerardina Smaldone, Francesca Di Matteo, Sara Novi, Mario Felice Tecce, Ornella Moltedo, Giuseppe Bifulco, Pietro Campiglia, Isabel M. Gomez-Monterrey, Robert Snoeck, Graciela Andrei, Carmine Ostacolo, Alessia Bertamino |
| 99 |
[GO] |
2021―Sep―21 |
Synthesis and antiviral activity of fatty acyl conjugates of remdesivir against severe acute respiratory syndrome coronavirus 2 and Ebola virus |
Naglaa Salem El-Sayed, Alexander S. Jureka, Megan R. Edwards, Sandeep Lohan, Caroline G. Williams, Patrick T. Keiser, Robert A. Davey, Jennifer Totonchy, Rakesh K. Tiwari, Christopher F. Basler, Keykavous Parang |
| 100 |
[GO] |
2021―Aug―18 |
Discovery of juglone and its derivatives as potent SARS-CoV-2 main proteinase inhibitors |
Jiahua Cui, Jinping Jia |
| 101 |
[GO] |
2021―Jul―05 |
System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2 |
Ilaria Vicenti, Maria Grazia Martina, Adele Boccuto, Marta De Angelis, Giorgia Giavarini, Filippo Dragoni, Serena Marchi, Claudia Maria Trombetta, Emmanuele Crespan, Giovanni Maga, Cecilia Eydoux, Etienne Decroly, Emanuele Montomoli, Lucia Nencioni, Maurizio Zazzi, Marco Radi |
| 102 |
[GO] |
2021―Jun―10 |
Discovery and optimization of 2-((1H-indol-3-yl)thio)-N-benzyl-acetamides as novel SARS-CoV-2 RdRp inhibitors |
Guo-Ning Zhang, Jianyuan Zhao, Quanjie Li, Minghua Wang, Mei Zhu, Juxian Wang, Shan Cen, Yucheng Wang |
| 103 |
[GO] |
2021―May―30 |
Improved SARS-CoV-2 Mpro inhibitors based on feline antiviral drug GC376: structural enhancements, increased solubility, and micellar studies |
Wayne Vuong, Conrad Fischer, Muhammad Bashir Khan, Marco J. van Belkum, Tess Lamer, Kurtis D. Willoughby, Jimmy Lu, Elena Arutyunova, Michael A. Joyce, Holly A. Saffran, Justin A. Shields, Howard S. Young, James A. Nieman, D. Lorne Tyrrell, M. Joanne Lemieux, John C. Vederas |
| 104 |
[GO] |
2021―May―05 |
A Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease |
Adam G. Kreutzer, Maj Krumberger, Elizabeth M. Diessner, Chelsea Marie T. Parrocha, Michael A. Morris, Gretchen Guaglianone, Carter T. Butts, James S. Nowick |
| 105 |
[GO] |
2021―Mar―20 |
Structure-Based Drug Design of an Inhibitor of the SARS-CoV-2 (COVID-19) Main Protease Using Free Software: A Tutorial for Students and Scientists |
Sheng Zhang, Maj Krumberger, Michael A. Morris, Chelsea Marie T. Parrocha, Adam G. Kreutzer, James S. Nowick |
| 106 |
[GO] |
2021―Feb―15 |
Protease targeted COVID-19 drug discovery: What we have learned from the past SARS-CoV inhibitors? |
Sk. Abdul Amin, Suvankar Banerjee, Shovanlal Gayen, Tarun Jha |
| 107 |
[GO] |
2021―Feb―09 |
Discovery and Structural Optimization of 3-O-β-Chacotriosyl Oleanane-type Triterpenoids as Potent Entry Inhibitors of SARS-CoV-2 Virus Infections |
Hui Li, Chen Cheng, Sumei Li, Yan Wu, Zhihao Liu, Mingjian Liu, Jianxin Chen, Qiuyu Zhong, Xuesha Zhang, Shuwen Liu, Gaopeng Song |
| 108 |
[GO] |
2021―Jan―22 |
RNA-dependent RNA polymerase (RdRp) inhibitors: the current landscape and repurposing for the COVID-19 pandemic |
Lei Tian, Taotao Qiang, Chengyuan Liang, Xiaodong Ren, Minyi Jia, Jiayun Zhang, Jingyi Li, Minge Wan, Xin YuWen, Han Li, Wenqiang Cao, Hong Liu |
| 109 |
[GO] |
2021―Jan―13 |
The race to treat COVID-19: Potential therapeutic agents for the prevention and treatment of SARS-CoV-2 |
Irshad Ahmad |
| 110 |
[GO] |
2020―Sep―19 |
Primed for Global Coronavirus Pandemic: Emerging Research and Clinical Outcome |
Shakir Ahamad, Scotty Branch, Shea Harrelson, Mohd Kamil Hussain, Mohammad Saquib, Saeed Khan |
| 111 |
[GO] |
2020―Aug―06 |
The Development of Coronavirus 3C-Like Protease (3CLpro) Inhibitors from 2010 to 2020 |
Yuzhi Liu, Chengyuan Liang, Liang Xin, Xiaodong Ren, Lei Tian, Xingke Ju, Han Li, Yongbo Wang, Qianqian Zhao, Hong Liu, Wenqiang Cao, Xiaolin Xie, Dezhu Zhang, Yu Wang, Yanlin Jian |
| 112 |
[GO] |
2020―Aug―01 |
Potent inhibitors of SARS-CoV-2 3C-like protease derived from N-substituted isatin compounds |
Pei Liu, Hongbo Liu, Qi Sun, Hao Liang, Chunmei Li, Xiaobing Deng, Ying Liu, Luhua Lai |
| 113 |
[GO] |
2020―Jul―28 |
Potential treatment methods targeting 2019-nCoV infection |
Lu Zheng, Lina Zhang, Jiamin Huang, Kutty Selva Nandakumar, Shuwen Liu, Kui Cheng |
| 114 |
[GO] |
2020―Jul―15 |
COVID-19 treatment: Much research and testing, but far, few magic bullets against SARS-CoV-2 coronavirus |
Vladimir V. Kouznetsov |
| 115 |
[GO] |
2020―Jul―15 |
Flavaglines as natural products targeting eIF4A and prohibitins: From traditional Chinese medicine to antiviral activity against coronaviruses |
Canan G. Nebigil, Christiane Moog, Stéphan Vagner, Nadia Benkirane-Jessel, Duncan R. Smith, Laurent Désaubry |
| 116 |
[GO] |
2020―Jun―12 |
Fight against novel coronavirus: A perspective of medicinal chemists |
Sk. Abdul Amin, Tarun Jha |
| 117 |
[GO] |
2020―Jun―12 |
Synthesis of adenine dinucleosides SAM analogs as specific inhibitors of SARS-CoV nsp14 RNA cap guanine-N7-methyltransferase |
Rostom Ahmed-Belkacem, Priscila Sutto-Ortiz, Mathis Guiraud, Bruno Canard, Jean-Jacques Vasseur, Etienne Decroly, Françoise Debart |
| 118 |
[GO] |
2020―Jun―06 |
A Promising Antiviral Candidate Drug for the COVID-19 Pandemic: A Mini-Review of Remdesivir |
Chengyuan Liang, Lei Tian, Yuzhi Liu, Nan Hui, Guaiping Qiao, Han Li, Zhenfeng Shi, Yonghong Tang, Dezhu Zhang, Xiaolin Xie, Xu Zhao |
|
